BeiGene
BeiGene
BeiGene (pronounced: Bay-Jeen) is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative targeted and immune-oncology therapeutics.
Etymology
The name "BeiGene" is derived from the company's focus on the genetic basis of cancer, with "Bei" meaning "North" in Chinese, symbolizing the company's roots in Beijing, China.
History
BeiGene was founded in 2010 by Xiaodong Wang, a member of the United States National Academy of Sciences, and John V. Oyler, a former executive at several multinational pharmaceutical companies. The company was established with the goal of becoming a global leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.
Products and Services
BeiGene's portfolio includes both internally developed and in-licensed clinical-stage drug candidates. The company's lead products include Zanubrutinib, a BTK inhibitor for the treatment of various lymphomas, and Tislelizumab, a PD-1 antibody for various solid and hematological cancers.
Related Terms
See Also
External links
- Medical encyclopedia article on BeiGene
- Wikipedia's article - BeiGene
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski